Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Females at least 18 years of age
Histologically-confirmed metastatic breast cancer with low HER2 expression and at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST)
Karnofsky performance status at least 80%
Disease progression on/after up to 2 different chemotherapy regimens, including an anthracycline-containing therapy
Left ventricular ejection fraction (LVEF) at least 50%
Adequate liver function
You may not be if
Pleural effusions, ascites, or bone lesions as the only manifestation(s) of cancer
Pulmonary or central nervous system (CNS) metastases
Chemotherapy, radiotherapy, or immunotherapy within 4 weeks; or hormone therapy within 2 weeks of Day 1
Previous treatment with any drug that targets the HER2 receptor family
Previous treatment with corticosteroids as cancer therapy
